Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy.

Keratinocytes are potentially appealing vehicles for the delivery of secreted gene products because they can be transferred to human skin by the relatively simple procedure of grafting. Adult human keratinocytes can be efficiently propagated in culture with sufficient proliferative capacity to produce enough epidermis to cover the body surface of an average adult. However, the feasibility of delivering secreted proteins through skin grafting rests upon (i) the strength of the promoter in keratinocytes and (ii) the efficiency of protein transport through the basement membrane of the stratified epithelium and into the bloodstream. In this paper, we use transgenic technology to demonstrate that the activity of the human keratin 14 promoter remains high in adult skin and that keratinocyte-derived human growth hormone (hGH) can be produced, secreted, and transported to the bloodstream of mice with efficiency that is sufficient to exceed by an order of magnitude the circulating hGH concentration in growing children. Transgenic skin grafts from these adults continue to produce and secrete hGH stably, at approximately 1/10 physiological levels in the bloodstream of nontransgenic recipient mice. These studies underscore the utility of the keratin 14 promoter for expressing foreign transgenes in keratinocytes and demonstrate that keratinocytes can be used as effective vehicles for transporting factors to the bloodstream and for eliciting metabolic changes. These findings have important implications for considering the keratinocyte as a possible vehicle for gene therapy.

[1]  T. Sun,et al.  The 50- and 58-kdalton keratin classes as molecular markers for stratified squamous epithelia: cell culture studies , 1983, The Journal of cell biology.

[2]  E. Fuchs,et al.  Isolation, sequence, and expression of a human keratin K5 gene: transcriptional regulation of keratins and insights into pairwise control , 1989, Molecular and cellular biology.

[3]  H. Blau,et al.  Myoblasts in pattern formation and gene therapy. , 1993, Trends in genetics : TIG.

[4]  Elaine Fuchs,et al.  Changes in keratin gene expression during terminal differentiation of the keratinocyte , 1980, Cell.

[5]  J. Bluestone,et al.  An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. , 1995, Journal of immunology.

[6]  L. Bolund,et al.  Gene transfer into cultured human epidermis and its transplantation onto immunodeficient mice: an experimental model for somatic gene therapy. , 1994, The Journal of investigative dermatology.

[7]  L. Taichman,et al.  Systemic delivery of secreted protein by grafts of epidermal keratinocytes: prospects for keratinocyte gene therapy. , 1994, Human gene therapy.

[8]  Y. Barrandon,et al.  Expression of an exogenous growth hormone gene by transplantable human epidermal cells. , 1987, Science.

[9]  C. Compton,et al.  Permanent Coverage of Large Burn Wounds with Autologous Cultured Human Epithelium , 1984 .

[10]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[11]  R. Palmiter,et al.  Metallothionein-human GH fusion genes stimulate growth of mice. , 1983, Science.

[12]  E. Fuchs,et al.  Probing keratinocyte and differentiation specificity of the human K5 promoter in vitro and in transgenic mice , 1993, Molecular and cellular biology.

[13]  K. Turksen,et al.  Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. , 1992, Genes & development.

[14]  M. Heartlein,et al.  Long-term production and delivery of human growth hormone in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Garlick,et al.  Tissue- and stratum-specific expression of the human involucrin promoter in transgenic mice. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Fuchs,et al.  The epidermis: rising to the surface. , 1994, Current opinion in genetics & development.

[17]  R. Palmiter,et al.  Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. , 1989, Endocrinology.

[18]  A Luger,et al.  Decreased peripheral insulin sensitivity in acromegalic patients. , 1990, Experimental and clinical endocrinology.

[19]  A. Bartke,et al.  Neuroendocrine and Reproductive Consequences of Overexpression of Growth Hormone in Transgenic Mice , 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[20]  E. Fuchs,et al.  Programming gene expression in developing epidermis. , 1994, Development.

[21]  L. Mandarino,et al.  Effects of Growth Hormone on Insulin Action in Man: Mechanisms of Insulin Resistance, Impaired Suppression of Glucose Production, and Impaired Stimulation of Glucose Utilization , 1982, Diabetes.

[22]  Michael G. Rosenfeld,et al.  Dramatic growth of mice that develop from eggs microinjected with metallothionein–growth hormone fusion genes , 1982, Nature.

[23]  U. Lewis,et al.  Studies of GH secretion in mice by a homologous radioimmunoassay for mouse GH. , 1972, Endocrinology.

[24]  D. Liggitt,et al.  An evaluation of the functions of the 22-kilodalton (kDa), the 20-kDa, and the N-terminal polypeptide forms of human growth hormone using transgenic mice. , 1992, Endocrinology.

[25]  F. Watt,et al.  Towards gene therapy for haemophilia B using primary human keratinocytes , 1993, Nature Genetics.

[26]  D. Carter,et al.  Posttranscriptional regulation of rat growth hormone gene expression: increased message stability and nuclear polyadenylation accompany thyroid hormone depletion , 1992, Molecular and cellular biology.

[27]  D. Gordon,et al.  Systemic distribution of apolipoprotein E secreted by grafts of epidermal keratinocytes: implications for epidermal function and gene therapy. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Froesch,et al.  The insulin-like growth factors (IGF) of human serum: chemical and biological characterization and aspects of their possible physiological role. , 1981, Current topics in cellular regulation.

[29]  I. Robinson,et al.  High plasma insulin-like growth factor-II and low lipid content in transgenic mice: measurements of lipid metabolism. , 1994, The Journal of endocrinology.

[30]  H. Green,et al.  Seria cultivation of strains of human epidemal keratinocytes: the formation keratinizin colonies from single cell is , 1975, Cell.

[31]  E. Fuchs,et al.  Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Tjian,et al.  Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. , 1988, Genes & development.

[33]  L. Tsui,et al.  Homologous and heterologous enhancers modulate spatial expression but not cell-type specificity of the murine gamma F-crystallin promoter. , 1990, Development.

[34]  W. Daughaday,et al.  Somatomedin: Proposed Designation for Sulphation Factor , 1972, Nature.

[35]  Jack W. Szostak,et al.  Cloning yeast telomeres on linear plasmid vectors , 1982, Cell.

[36]  L. Bolund,et al.  Tissue culture of human epidermal keratinocytes: a differentiating model system for gene testing and somatic gene therapy. , 1991, Journal of cell science.

[37]  H. Green,et al.  Human growth hormone in the blood of athymic mice grafted with cultures of hormone‐secreting human keratinocytes , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  R. Hammer,et al.  Growth allometry of the organs in giant transgenic mice. , 1987, Endocrinology.

[39]  E. Fuchs,et al.  Retinoid-mediated transcriptional regulation of keratin genes in human epidermal and squamous cell carcinoma cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Perricaudet,et al.  Gene therapy using adenovirus vectors. , 1995, Current topics in microbiology and immunology.

[41]  H. Blau,et al.  Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. , 1991, Science.

[42]  S. Liebhaber,et al.  The human growth hormone gene is regulated by a multicomponent locus control region , 1995, Molecular and cellular biology.

[43]  L. Presta,et al.  Contribution to global protein stabilization of the N-capping box in human growth hormone. , 1994, Biochemistry.

[44]  S. Bidichandani,et al.  Circulating human factor IX produced in keratin-promoter transgenic mice: a feasibility study for gene therapy of haemophilia B. , 1995, Human molecular genetics.

[45]  R. Storb,et al.  Long-term transplantation of canine keratinocytes made resistant to G418 through retrovirus-mediated gene transfer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Cancedda,et al.  Clonal analysis of stably transduced human epidermal stem cells in culture. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Martial,et al.  Human growth hormone: complementary DNA cloning and expression in bacteria. , 1979, Science.

[48]  E. Fuchs,et al.  The expression of mutant epidermal keratin cDNAs transfected in simple epithelial and squamous cell carcinoma lines , 1987, The Journal of cell biology.

[49]  H. Green,et al.  Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes , 1977, Nature.

[50]  Yann Barrandon,et al.  Location of stem cells of human hair follicles by clonal analysis , 1994, Cell.

[51]  E. Fuchs,et al.  The basal keratin network of stratified squamous epithelia: defining K15 function in the absence of K14 , 1995, The Journal of cell biology.